Texas Oncology, P.A.

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Phase 1/2· Source

• Recruiting

  FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

  NCT05614739· Phase 1· Source

• Recruiting

  A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  NCT05377996· Phase 1/2· Source

• Recruiting

  CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

  NCT05029999· Phase 1· Source

• Active, not recruiting

  Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

  NCT04919811· Phase 2· Source

• Active, not recruiting

  Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

  NCT04498117· Phase 3· Source

• Active, not recruiting

  Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

  NCT02811861· Phase 3· Source

• Active, not recruiting

  PhII ICb With/Without Erbitux in MBC Pts

  NCT00248287· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer2 recruiting
• Endometrial cancer2 recruiting
• Ovarian cancer2 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· Phase 2· Source